BergenBio and Oncoinvent has signed an agreement for a merger in which BerGenBio will become the acquiring company. The merger, which values BerGenBio at NOK 65 million and Oncoinvent at NOK 195,5 million, is followed by a guaranteed rights issue of NOK 130 million. The issue will finance Oncoinvent's clinical development of Radspherin until 2027. The merger is supported by the major owners Meteva and Hadean Ventures, and is expected to be completed in September 2025.
|
Published July 1, 2025
BerGenBio and Oncoinvent plan merger
Notes
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account